Theratechnologies inc.

Theratechnologies inc.

December 07, 2007 12:43 ET

Media Advisory and Audio Webcast: Theratechnologies Discloses its Market Size Estimation for HIV-Associated Lipodystrophy

MONTREAL, CANADA--(Marketwire - Dec. 7, 2007) - Theratechnologies (TSX:TH) advises of an upcoming Analyst Day meeting and audio webcast to discuss its recent HIV-associated lipodystrophy market research studies, conducted with patients, physicians and payers.

The Analyst Day, which will take place in Toronto on Monday, December 10, 2007, from 8:45 a.m,. to 2:00 p.m. Eastern Time, is by invitation only and will be retransmitted live on the web for the general public. A press release will also be issued on the morning of December 10, 2007.

December 10, 2007 webcast

For the audio webcast access, interested participants are asked to go to one of the following links: or A replay of the audio webcast will be available from December 10, 2007 at 5:00 p.m. to December 12, 2007 at 11:59 p.m.

About Theratechnologies

Theratechnologies (TSX:TH) is a Canadian biopharmaceutical company that discovers innovative drug candidates in order to develop them and bring them to market. The Company targets unmet medical needs in financially attractive specialty markets. Its most advanced program is tesamorelin, now in a confirmatory Phase 3 clinical trial for a serious metabolic disorder known as HIV-associated lipodystrophy. The Company also has other projects at earlier stages of development.

Contact Information